The gene editing startup, a spinout from Yale University, has launched with funding from investors including GV and Kleiner Perkins.

US-based in-vivo gene editing technology developer Trucode Gene Repair emerged from stealth yesterday with $34m in funding from investors including GV, a corporate venturing vehicle for internet technology conglomerate Alphabet. The round also featured venture firm Kleiner Perkins. GV general partner Krishna Yeshwant has joined Trucode’s board of directors with Kleiner Perkins’ Beth Seidenberg; Andrew…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.